Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 study of LB-208 in relapsed or refractory AML and higher-risk MDS
2025-523396-38-00Phase 2Authorised
- Sponsor
- AOP Health
- Start
- May 2026
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of AOP208 in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), sponsored by AOP Health. Primary endpoint: Safety and toxicity. Planned start May 2026; status: authorised.
02
Drugs
AOP208
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on 2025-523396-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523396-38-00.